Balaxi Pharmaceuticals Limited files a mandatory RTA report with NSE confirming zero requests for re-lodgement of physical share transfers.
The nil report for April 2026 is submitted in compliance with SEBI circular HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026.
The company's RTA, Aarthi Consultants Private Limited, confirmed no requests were received, processed, approved, or rejected during the period.